TABLE 2.
Relapses, Hepatic Decompensation, and Fatal Outcomes in HBeAg‐Negative Patients After NA Discontinuation (Selected Studies)
| Study | Number of Patients With Cirrhosis, n | HBV‐DNA Relapse, n (%) | ALT Relapse, n (%) | Hepatic Decompensation, n (% Cirrhosis) | Death, n (% Cirrhosis) |
|---|---|---|---|---|---|
| Lim et al.( 82 ) (two case reports) | 2 | 2 (100) | 2 (100) | 2 (100) | 1 (100) |
| Jeng et al.( 65 ) | 691 (308) | 547 (79.2)* | 419 (60.6)† | 9 (100) | 3 (100) |
| Kuo et al.( 66 ) | 22 | N/A | 82 (68.4) | 1 (100) | 1 (100) |
*
Increase of HBV DNA > 2,000 IU/mL.
†
increase of ALT > 2× ULN.